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A number of recently published results have suggested the possibility of using stem cells to
regenerate lung tissue. Several groups have developed various animal models employing hae-
matopoietic stem cells, mesenchymal and endothelial progenitors, and embryonic cells, in
which it has been possible to ameliorate the diseased lung. Despite these stimulating in vivo
results a number of questions are pending before stem cell derivatives can be used in human
lung disorders. This brief review will examine encouraging data that suggest the possibility of
using stem cells in the therapy of lung diseases. In parallel, controversial findings are reviewed
indicating that caution should be recommended before proposing to utilize stem cells in human
lung diseases.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
At present allogeneic lung transplantation is considered the
only treatment option for progressive and irreversible lung
diseases. Unfortunately, the number of donors is not suffi-
cient to meet demand and the open problem of the
prevention and treatment of chronic rejection are weak
points that limit the use of this approach.
Stem cell therapy holds great promise for the future of
transplantation in respiratory medicine. In fact, the capa-
bility of stem cells to locally repair damaged tissue offers the
possibility for cell-based treatment of most irreversible
diseases, including chronic lung diseases. This consideration49 8754179.
pd.it
0 Elsevier Ltd. All rights reservedexplains why many research groups are looking at the
manipulation of stem cells as a way to augment lung repair
and improve the response of the lung parenchyma to injury
anddisease. Thehope is to obtain abiological solution for the
several degenerative conditions and genetic diseases that
may affect the lung.
In this brief review we will briefly comment on a series of
recently published results on the possibility of using stem
cells to regenerate lung tissue. Several groups have devel-
oped animal models employing haematopoietic stem cells,
mesenchymal and endothelial progenitors, and embryonic
cells, in which it has been possible to obtain functional
representatives of the cell types of the respiratory system.
In several cases the engraftment of these cells in the lung
has ameliorated the diseased lung of the animal. Despite
these stimulating results in vivo a number of questions are
pending before stem cell derivatives are used in human.
Stem cell therapy for chronic lung diseases S87lung disorders. First, the question remains as to whether
the extraction of stem cells from embryos is justified.
Furthermore, methods for instructing haematopoietic or
embryonic stem cells to differentiate into specific func-
tional respiratory tissues are not fully standardized.1 Also,
it is known that derivatives from allogeneic and embryonic
stem cells engrafting the respiratory tract may be rejected,
suggesting the need for better understanding of the local
immune response in organs after stem cells engraft. The
hopes and controversies surrounding the use of stem cells in
the therapy of lung diseases will be faced in the next
paragraphs.Haematopoietic stem cells for lung diseases
The exciting properties of stem cells were first recognized
in the bone marrow. Three different stem cell populations
can be isolated from an aspirate of bone marrow. The first
is haematopoietic stem cells (HSCs), which are very rare (1
in 104e105 bone marrow cells). They may be easily purified
using the cell surface marker CD34 or, alternatively, CD133
and aldehyde dehydrogenase (ALDH). Functional studies of
isolated CD34 cells have shown that high expression of
CD34 and ALDH characterizes HSCs able to give multi-
lineage haematopoietic repopulation.2 One essential
feature of HSCs is their ability to self-renew, i.e. go
through several cycles of cell division without becoming
differentiated. This ability is crucial because more differ-
entiated cells such as haematopoietic progenitors cannot
stem, even though most progenitors are able to expand for
a limited period of time after being generated. Interest-
ingly, HSCs may be found not only in the bone marrow but
also in cord blood, which may be an interesting alternative
source for CD34þ cells.
A second bone marrow population of precursors is
formed by mesenchymal stem cells (MSC).3 Specific markers
for these cells have not definitively been identified in
humans, although MSCs have been isolated from the bone
marrow of rodents using CD150þ CD48 and Sca-1þ Lin c-
Kitþ selection criteria. In any case it is generally accepted
that MSCs are very rare (0.5e5 in 105 cells in mice and 1e20
in 105 cells in humans).
Endothelial progenitor cells (EPCs) represent the third
bone marrow-derived population of HSCs.4 VEGFR2, c-Kit,
CD34 and CD133 are used to identify human EPCs, which are
characteristically CD45-negative. In rodents Sca-1 is added
to the panel of EPC markers. These cells are involved in
neovascularization phenomena both in physiological and
pathological conditions, including chronic lung diseases.6
Bone marrow stem cells are considered as progenitor
cells that maintain their potential to differentiate and give
rise to a number of solid organs if cultured in appropriate
conditions. In particular, there are data suggesting that
these cells may differentiate into non-stromal tissues,
including lung epithelium. For example, Lobinger et al.6
have shown that bone marrow-derived progenitors have
the ability to differentiate and function as airway and
parenchymal lung cells. It is important to note that the
specific bone marrow cell population(s) that is (are)
capable of differentiating into lung cells has not been fully
identified or characterized. Possible candidates includesubsets of HSCs or MSCs. These latter cells of mesodermal
origin are considered to be the bone marrow progenitor
cells with the highest expansion potential toward lung
cells.
The multipotency of MSCs is demonstrated by their
ability to give rise to a number of differentiated cells,
including muscle, fat, vascular, blood, connective and
elements of the pulmonary tract. Not only MSCs of bone
marrow origin but also those derived from cord blood may
acquire the phenotype of lung cells.7 This is suggested by
the evidence that after adequate stimulation they co-
express markers of lung epithelium cells (cytokeratin),
myofibroblasts (smooth muscle actin) and prosurfactant
protein B or C, all of which are known to be expressed by
type 2 alveolar epithelial cells.
BonemarrowMSCs retain the ability tomigrate to tissues,
including the lung. After sex-mismatched bone marrow
transplantation, bonemarrow-derived cells containing the Y
chromosome may be detected in the respiratory tract of
transplanted mice by fluorescence in situ hybridization
techniques.8 It is also clear that lung injury increases the
recruitment of adult marrow-derived cells to the lung, sug-
gesting that unknown chemotactic signals released by
injured or remodelling lung serve to attract marrow-derived
stem cells. In this regard our understanding of how growth
and differentiation of bone marrow-derived MSCs is regu-
lated by interactions with resident lung cells or locally
released growth factors and cytokines is still incomplete.Our
group is investigating signalling mechanisms that favour
growth and differentiation of MSCs during chronic lung
diseases characterized by injury and remodelling.
The participation of MSCs in human lung regeneration is
suggested by data indicating that newly recruited MSCs
engraft the host pulmonary tract. Chimerism for both
epithelial and endothelial cells can be demonstrated in lung
specimens from allogeneic bone marrow transplant recipi-
ents.9,10 Similarly, lung specimens from patients undergoing
allogeneic lung transplantation may demonstrate chime-
rism of lung epithelium.11 The bone marrow population
showing migratory capabilities begins to be characterized.
Data in rodents suggest that specific adult marrow cell
populations (e.g. those expressing the chemokine receptor
CXCR4) may be recruited into the lung.12 Other data
demonstrate that circulating precursors expressing the
chemokine receptor CXCR4, but not CD34, CD15, CD68 or c-
Kit, are bone marrow-derived precursors able to engraft the
lung.13
Concerning the molecular mechanisms that direct the
migration of HSCs, it is known that chemokines are impli-
cated in the recruitment of adult stem cells and their
progeny. Chemokines are actively released by injured or
remodelling lung, attracting marrow-derived stem cells.
However, expression of specific adhesion molecules or
proteins by injured or remodelling lung favours the local
homing of newly recruited bone marrow-derived cells. As
confirmation, bleomycin increases the pulmonary expres-
sion of stromal cell-derived factor 1 (SDF1/CXCL12), a che-
mokine that plays an important role in angiogenesis by
recruiting EPCs from the bone marrow through a CXCR4-
dependent mechanism.12
The hypothesis that bone marrow-derived cells may be
used for regenerative purposes in lung diseases is confirmed
S88 C. Agostiniby the fact that these cells engraft in the lung, acquire
characteristics of certain respiratory cell populations and,
in some cases, reduce the degree of experimental respi-
ratory fibrosis. In mouse models of fibrosis, emphysema and
inflammatory lung injury, bone marrow cells appear to
partially abrogate lung injury.8 In a rat model it has been
shown that once newly recruited EPCs have engrafted the
arteriolar bed they are able to prevent the progression of
pulmonary arterial hypertension.14 However, increased
levels of EPCs are associated with improved outcome from
acute lung injury in bacterial pneumonia.15
There are also data in humans confirming the clinical
potential of bone marrow-derived stem cells in lung
diseases. Transplantation with autologous bone marrow
stem cells is used for therapeutic purposes in patients with
connective tissue or autoimmune disorders and lung
involvement. Using bone marrow-derived MSCs it has been
possible to restore the altered expression of cystic fibrosis
transmembrane conductance regulator (CFTR), which is
defective in patients with cystic fibrosis. This has been
done by mixing transduced bone marrow cells in culture
with primary airway epithelial cells obtained from patients
with cystic fibrosis.16 The possibility of restoring the
defective CFTR expression has been confirmed in animal
models, since wild-type bone marrow cells are able to
engraft the lungs of CFTR knockout mice and acquire
epithelial phenotypes, including the expression of CFTR
messenger RNA and protein.17
More recently, the first tissue-engineered trachea,
utilizing the patient’s own stem cells, has been successfully
transplanted into a young woman who, following a severe
case of tuberculosis, had a collapse of the left main bron-
chus.18 A brief description of the tissue-engineering
protocol follows.
Using a new technique developed at Padua University
the trachea was decellularized over a 6-week period so that
no donor cells remained. Autologous haematopoietic stem
cells were obtained from the recipient’s own bone marrow,
cultured in vitro in the presence of a mix of growth factors
and matured into chondrocytes. In parallel, autologous
epithelial cells were isolated and expanded by bronco-
scopic biopsy samples of the right main bronchial mucosa.
The donor’s tissue scaffold was then re-seeded with cells
from the recipient, i.e. chondrocytes on the outer surface
and epithelial cells on the inner surface, using a specially
designed bioreactor. Once the donor’s cells were attached
the scaffold was transplanted after removal of the stenotic
bronchus.Table 1 Controversies in the use of stem cells for lung disease
Is engraftment always sufficient for regenerative purposes? Data
at a very low level.
Can engrafted stem cells be rejected? The problem is crucial if u
less important when using autologous stem cells.
Which cells are engrafting in the diseased lung (mesenchymal or
cells etc.)? In particular, are we sure that the ideal precursor i
Could stem cells cause local damage rather than be curative (fav
Will engrafted stem cells have the potential to form tumours ove
stem cells may have karyotype abnormalities, and tissue stemThe bioengineered trachea immediately provided the
patient with a normally functioning airway. During follow-
up the patient did not develop antibodies to the graft,
although she was not taking immunosuppressive drugs.
More importantly, lung function tests performed 4 months
after transplantation remained in the normal range, obvi-
ously improving the patient’s quality of life. This finding
suggests that autologous cells could be used for the treat-
ment of patients with devastating airway diseases if the
technique were applied in the context of an appropriate
bioengineering protocol.
Despite these exciting findings caution is recommended
before proposing to utilize HSCs extensively in lung diseases
(Table 1). It must be considered that an excessive growth of
autologous stem cells might contribute to the pathogenesis
of chronic lung diseases. For example, EPCs have been
involved in both pulmonary vascular remodelling in mouse
models of pulmonary hypertension19 and lung repair in
acute and chronic lung injury.5 However, MSCs and EPCs, by
providing a supportive stroma for neoplastic cells, are
suspected to contribute to the development of lung cancer
and other malignancies in mouse models.20 We recently
demonstrated that cells showing stem cell markers such as
CD34 can be demonstrated near fibroblast foci in idiopathic
pulmonary fibrosis, suggesting a role for CD34 cells in the
accretion of the fibroblast focus (submitted for publica-
tion). Furthermore, there are data indicating that circu-
lating precursors of fibroblasts may participate in lung
remodelling in chronic lung diseases characterized by
fibrosing injuries.21Embryonic stem cells for lung diseases
Throughout childhood stem cells are critical for develop-
ment and growth. Only the fertilized oocyte and cells
derived from the first two divisions are completely totipo-
tent, since after about 4 days they begin to specialize and
form the blastocyst, a structure that contains a cluster of
cells called the inner cell mass (ICM), from which the
embryo develops. ICM cells are pluripotent e they are able
to differentiate into almost any cell that arises from the
three germ layers.
Pluripotent embryonic stem cells (ESCs) offer potential
as a source of lung cell types of endodermal, mesodermal or
ectodermal origin. ESCs taken from the ICM have the
advantage of an unequalled pluripotent differentiation
plasticity associated with a robust repair capacity in mosts.
in animal models suggest that it may occur
sing allogeneic haematopoietic or embryonic stem cells,
haematopoietic stem cells, endothelial progenitor
s engrafting?
ouring fibrosis, asthma etc.)?
r longer periods of time? There is evidence that engrafted
cells seem to be involved in lung neoplasms.
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without limit and contribute to any cell type, human ESCs
offer unprecedented access to tissues from the human
body. Nonetheless, the use of ICM cells involves the
destruction of the embryo, which has moral and ethical
implications in most countries.
Methods for obtaining lung epithelium from cells of the
endodermal lineage are considerably more difficult than
those used to obtain cells from the mesodermal or ecto-
dermal germ layers.1 Despite this, several studies using
different methods have demonstrated the development of
cells with the lung epithelial phenotype from murine
embryonic stem cells.22 For example, mouse ESCs can be
induced to express prosurfactant B, a marker of type 2
alveolar epithelial cells, and prosurfactant C.
When the ESC derivatives were employed in an attempt
to repair injured lung tissue in vivo, a number of problems
emerged.1,22 After the injection of ESC, pulmonary locali-
zation of implanted cells was observed at very low
frequency in injured animals. The rate of ESC engraftment
was barely detectable, with only 10e20 cells per lung
detected, likely as a consequence of widespread induction
of apoptosis.1 The next stage of the research will be to
evaluate the molecular basis and signalling that favour the
implantation of ESC, including in the lung, and whether
engraftment may be augmented therapeutically.
There are also concerns about the potential for the
malignant transformation of ESC in the lung, as has been
described in other organs. Embryonic stem cells have
a tendency to develop into specific kind of tumours when
they are implanted into mice during different experimental
conditions. Specifically, teratomas may develop from
pluripotent cells23 and consist of different tissue elements
from one or more of the three germ cell layers. Recent
findings suggest that the processes of stem cell reprog-
ramming and cancer stem cell induction may overlap. This
possibility highlights the importance of studies designed to
define the transcriptional and signalling networks involved
in normal and cancer stem cell development. Only with
a better understanding of these processes will it become
possible to develop cellular reprogramming methods for use
in regenerative medicine without undue risk of cancer stem
cell development in the engrafted lung. As an example, the
survivin gene (BIRC5) is especially highly expressed in
undifferentiated human embryonic stem cells and their
derived tumours.24 On the basis of these data it has been
proposed that a strategy inhibiting BIRC5 expression close
to stem cell transplantation should minimize the risk of
tumour formation.
Finally, it is not clear whether lung cells derived from
pluripotent embryonic stem cells can be rejected after their
engraftment. Since ESC are characterized by poor immu-
nogenicity because of their low expression of HLA, it has
been suggested that ESC are immune privileged in alloge-
neic combinations.25 Their propensity for tolerance could be
also attributed to the paucity of professional antigen-
presenting cells and the expression of transforming growth
factor b2.26 Nonetheless, ESCs are not protected against
cytotoxic T-lymphocyte-mediated cytotoxicity. For instance
Wu et al.,27 examining the adaptive immune response
against terminally differentiated insulin-producing tissue
derived from an ESC source, clearly demonstrated thatfunctional ESC-derived insulin-producing tissue was infil-
trated by alloreactive T cells and rejected in immunocom-
petent hosts. Thus, the immune privilege of ESCs and their
terminally differentiated derivatives is fragile. As a result, it
appears that ESCs may represent targets for attack by
elements of the immune system and can be rejected.
Whether there are differences in the robustness of immune
privilege among different tissues derived from ESC remains
unclear. Hope in this field rests on the strategies that are
being pursued to generate pluripotent stem cells for use in
autologous or allogeneic transplantation and are able to
prevent the immunological rejection of transplanted human
stem cells into a recipient host.28,29Tissue adult stem cells for lung diseases
A limited tissue pool of stem cells may represent the source
of cells for the regeneration and repair phenomena seen in
slowly renewing tissues, including the respiratory tract.
Tissue stem cells, which have been demonstrated in
different organs, are considered to be unspecialized cells
showing the capacity for unlimited self-renewal and the
ability to produce more differentiated committed cells.
The endogenous stem cells of the respiratory tract have
been identified and isolated. Kim et al.30 found that bron-
choalveolar stem cells (BASCs) are able to maintain
homeostasis of bronchiolar and alveolar epithelial cells.
These cells are found at the bronchoalveolar ductal junc-
tion, i.e. the segment of the respiratory epithelium in
which the terminal bronchioles are contiguous with the
alveolar epithelium. Thus it is believed that this portion of
lung tissue represents the putative niche for lung stem
cells. BASCs express stem cell markers (CD34 and Sca-1),
Clara cell markers (CCSP, Clara cell secretory protein) and
surfactant protein C (SP-C) and, at resting normal condi-
tions, are quiescent. In response to injury of the bronchial
and alveolar epithelium BASCs acquire the capability to
proliferate. Furthermore, BASCs retain multilineage
differentiation capacity: in culture they are able to give
rise to epithelial colonies containing squamous alveolar
type 1 pneumocytes (AT1) and cuboidal alveolar type 2
pneumocytes (AT2). Recent data have shown that Gata6
regulates a Wnt-mediated pathway required for BASC-
dependent regeneration after lung injury.31
The therapeutic potential of these niche cells remains to
be defined. For instance, it is unclear if there is a BASC
counterpart for non-epithelial pulmonary cells. Further-
more, the isolation of BASCs is not easy and the number of
BASC cells that may be retrieved for therapeutic purposes is
quite limited.32 Technologies will need to be developed in
order to isolate and expand in vitro these particular cell
populations in animal models of lung injury. It should also
be noted that it remains to be established whether BASCs
are involved in lung pathogenesis. Cells expressing AT2,
CCSP, and SP-C (i.e. the phenotype of BASC) have been
identified in murine tumours of the lung that express the
oncogene K-ras. In brief, whether endogenous lung stem
cells may participate in the development of lung carcinoma
in humans is not clear.
For instance, Yanagi et al.33 have shown that Pten,
a tumour suppressor gene, is essential for BASC homeostasis,
S90 C. Agostinileading to normal lung morphogenesis and allowing the
prevention of lung carcinogenesis. Bmi1, a dysregulated gene
that is associated with lung cancer, plays a key role in regu-
lating the proliferation of both BACS and tumour cells in
diverse adult epithelial tissues,34 providing a molecular link
between putative endogenous lung stem cells that reside in
the respiratory tract and lung, and tumourigenesis.
However, BASCs possess a unique profile of microRNAs
(miRNAs), a recently discovered class of small nucleic acids
(approximately 18e24 nucleotides) that negatively regulate
gene expression.35 BASCs show altered expression of
several microRNAs, such as miR-142-3p, miR-451, miR-106a,
miR-142-5p, miR-15b, miR-20a, miR-106b, miR-25 and miR-
486, compared with control cells, suggesting that micro-
RNAs might play important roles in maintaining the self-
renewal capacity of BASCs, but also suggesting that that
aberrant expression of microRNAs could be involved in
turning BASCs into lung cancer stem cells. Taken together
these points clearly indicate that the delicate balance
between signals regulating homeostasis, regeneration and
tumourigenesis must be investigated in detail before any
proposal to use endogenous stem cells for the therapeutic
management of lung injury.
Conclusions
In the last few years many potential sources of stem and/or
progenitor cells have been identified. A major challenge for
the future will be to characterize the selective cell pop-
ulations that are committed to remodelling during growth
and repair after lung injury. A significant emphasis must be
placed on developing and standardizing techniques aimed
at making the process of stem cell engraftment safe and
routine. In parallel, rigorous in vivo preclinical testing in
animal models is needed. These steps are necessary before
proposing the therapeutic use of stem cells for the variety
of pulmonary diseases in which regenerative medicine
could be helpful.
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